What is there to disagree on? Shareholders expected a buyout and they didn't get it. As far as the deal, $200M upfront for a 10th in line me-too drug with another $250M or whatever in milestones and from novartis (not purdue) all with no patent is as good as it gets.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.